PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07K 16/22, C12N 15/13, 15/63, 15/70, A61K 39/395

A3

(11) International Publication Number:

WO 98/45331

(43) International Publication Date:

15 October 1998 (15.10.98)

(21) International Application Number:

PCT/US98/06604

(22) International Filing Date:

3 April 1998 (03.04.98)

(30) Priority Data:

08/833,504 7 April 1997 (07.04.97) US 08/908,469 6 August 1997 (06.08.97) US

(71) Applicant (for all designated States except US): GENENTECH, INC. [US/US]; One DNA Way, South San Francisco, CA 94080 (US).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): BACA, Manuel [AU/US]; Apartment #H3, 888 Foster City Boulevard, Foster City, CA 94404 (US). WELLS, James, A. [US/US]; 1341 Columbus Avenue, Burlingame, CA 94010 (US). PRESTA, Leonard, G. [US/US]; Apartment 206, 1900 Gough Street, San Francisco, CA 94109 (US). LOWMAN, Henry, B. [US/US]; 400 San Juan Avenue, El Granada, CA 94018 (US). CHEN, Yvonne, Man—Yee [CA/US]; 1951 O'Farrell Street #321, San Mateo, CA 94403 (US).
- (74) Agents: DREGER, Walter, H. et al.; Flehr, Hohbach, Test, Albritton & Herbert LLP, Suite 400, 4 Embarcadero Center, San Francisco, CA 94111-4187 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.


(88) Date of publication of the international search report:

3 December 1998 (03.12.98)

(54) Title: ANTI-VEGF ANTIBODIES

(57) Abstract

Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells *in vitro*, and inhibit tumor growth *in vivo*.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

Albania	ES	Spain	LS	Lesotho	SI	Slovenia
Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
Austria	FR	France	LU	Luxembourg	SN	Senegal
Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
Brazil	IL	Israel	MR	Mauritania	UG	Uganda
Belarus	IS	Iceland	MW	Malawi	US	United States of America
Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
Switzerland	KG	Kyrgyzstan	NO	Norway	$\mathbf{z}\mathbf{w}$	Zimbabwe
Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
Cameroon		Republic of Korea	PL	Poland		
China	KR	Republic of Korea	PT	Portugal		
Cuba	KZ	Kazakstan	RO	Romania		
Czech Republic	LC	Saint Lucia	RU	Russian Federation		
Germany	LI	Liechtenstein	SD	Sudan		
Denmark	LK	Sri Lanka	SE	Sweden		
Estonia	LR	Liberia	SG	Singapore		
=						
	Armenia Austria Austria Australia Azerbaijan Bosnia and Herzegovina Barbados Belgium Burkina Faso Bulgaria Benin Brazil Belarus Canada Central African Republic Congo Switzerland Côte d'Ivoire Cameroon China Cuba Czech Republic Germany Denmark	Armenia FI Austria FR Austria FR Australia GA Azerbaijan GB Bosnia and Herzegovina GE Barbados GH Belgium GN Burkina Faso GR Bulgaria HU Benin IE Brazil II Belarus IS Canada IT Central African Republic JP Congo KE Switzerland KG Côte d'Ivoire KP Cameroon China KR Cuba KZ Czech Republic LC Germany LI Denmark LK	Armenia FI Finland Austria FR France Australia GA Gabon Azerbaijan GB United Kingdom Bosnia and Herzegovina GE Georgia Barbados GH Ghana Belgium GN Guinea Burkina Faso GR Greece Bulgaria HU Hungary Benin IE Ireland Brazil IL Israel Belarus IS Iceland Canada IT Italy Central African Republic JP Japan Congo KE Kenya Switzerland KG Kyrgyzstan Côte d'Ivoire KP Democratic People's Cameroon Republic of Korea China KR Republic of Korea Cuba KZ Kazakstan Czech Republic Germany LI Liechtenstein Jenoro Linica Licelcand Canada KI Licelcand Carmany LI Liechtenstein LE Garon Gabon Saint Lucia LI Liechtenstein LI Liechtenstein LI Liechtenstein	Armenia FI Finland LT Austria FR France LU Australia GA Gabon LV Azerbaijan GB United Kingdom MC Bosnia and Herzegovina GE Georgia MD Barbados GH Ghana MG Belgium GN Guinea MK Burkina Faso GR Greece Bulgaria HU Hungary ML Benin IE Ireland MN Brazil IL Israel MR Belarus IS Iceland MW Central African Republic JP Japan NE Congo KE Kenya NL Switzerland KG Kyrgyzstan NO Côte d'Ivoire KP Democratic People's NZ Cameroon REPUBLIC REPUBLIC REPUBLIC ROLL China KR Republic OF Korea PL Cotach Republic LC Saint Lucia RU Germany LI Liechtenstein SD Denmark LK Sri Lanka SE	Armenia FI Finland LT Lithuania Austria FR France LU Luxembourg Australia GA Gabon LV Latvia Azerbaijan GB United Kingdom MC Monaco Bosnia and Herzegovina GE Georgia MD Republic of Moldova Barabados GH Ghana MG Madagascar Belgium GN Guinea MK The former Yugoslav Burkina Faso GR Greece Republic of Macedonia Bulgaria HU Hungary ML Mali Benin IE Ireland MN Mongolia Brazil IL Israel MR Mauritania Belarus IS Iceland MW Malawi Canada IT Italy MX Mexico Central African Republic JP Japan NE Niger Congo KE Kenya NL Netherlands Switzerland KG Kyrgyzstan NO Norway Côte d'Ivoire KP Democratic People's NZ New Zealand Cameroon Republic of Korea PL Poland China KR Republic of Korea PT Portugal Czech Republic LC Saint Lucia RU Russian Federation Germany LI Liechtenstein SD Sudan Denmark LK Sri Lanka SE Sweden	Armenia FI Finland LT Lithuania SK Austria FR France LU Luxembourg SN Australia GA Gabon LV Latvia SZ Azerbaijan GB United Kingdom MC Monaco TD Bosnia and Herzegovina GE Georgia MD Republic of Moldova TG Barbados GH Ghana MG Madagascar TJ Belgium GN Guinea MK The former Yugoslav TM Burkina Faso GR Greece Republic of Macedonia TR Bulgaria HU Hungary ML Mali TT Benin IE Ireland MN Mongolia UA Brazil IL Israel MR Mauritania UG Belarus IS Iceland MW Malawi US Canada IT Italy MX Mexico UZ Central African Republic JP Japan NE Niger VN Congo KE Kenya NL Netherlands YU Switzerland KG Kyrgyzstan NO Norway ZW Côte d'Ivoire KP Democratic People's NZ New Zealand Cameroon Republic of Korea PL Poland China KR Republic of Korea PT Portugal Cuba KZ Kazakstan RO Romania Czech Republic LC Saint Lucia RU Russian Federation Germany LI Liechtenstein SD Sudan Denmark LK Sri Lanka SE Sweden

into ional Application No PCT/US 98/06604

A. CLASS CLASSIFICATION OF SUBJECT MATTER C12N15/70 A61K39/395 C12N15/13 C12N15/63C07K16/22 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) IPC 6 C07K C12N A61K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. WO 92 22653 A (GENENTECH INC) 7,10-13,χ 23 December 1992 25-27 1,4,14, Υ the whole document and specially: see SEQ.ID.N. 17,18 and 25 15,22, 28-31, see page 5, line 24 - page 7, line 35 34-38 see page 9, line 22 - page 10, line 4; figure 5 KIM ET AL.,: "Inhibition of vascular 1,4,14, Υ 15,22, endothelial growth factor-induced 28-31, angiogenesis suppresses tumor growth in 34 - 38vivo" NATURE. vol. 362, 1993, page 841 XP002013864 London, GB cited in the application see abstract Patent family members are listed in annex. Further documents are listed in the continuation of box C. χ Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance invention "E" earlier document but published on or after the international "X" document of particular relevance; the claimed invention filing date cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu-"O" document referring to an oral disclosure, use, exhibition or ments, such combination being obvious to a person skilled in the art. other means "P" document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of mailing of the international search report Date of the actual completion of theinternational search 02/10/1998 18 September 1998 Authorized officer Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Mateo Rosell, A.M. Fax: (+31-70) 340-3016

1

Inte ional Application No
PCT/US 98/06604

C.(Continua	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category 3	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	GB 2 268 744 A (CELLTECH LTD) 19 January 1994 see abstract see page 4, paragraph 3 - page 6, paragraph 1	1,32-41
A	M.M. BENDIG: "Humanization of rodent monoclonal antibodies" METHODS: A COMPANION TO METHODS IN ENZYMOLOGY, vol. 8, 1995, pages 83-93, XP000647344 New York, NY, US see the whole document	1,34-38
P,X	M. BACA ET AL., : "Antibody humanization using monovalent phage display" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 16, 18 April 1997, pages 10678-10684, XP002077471 see the whole document	1-42

1

ernational application No.

INTERNATIONAL SEARCH REPORT

PCT/US 98/06604

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: 5 AND 39-42 because they relate to subject matter not required to be searched by this Authority, namely: Remark: Although claims 5 and 39-42 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application. as follows:
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invitepayment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

Information on patent family members

Int tional Application No
PCT/US 98/06604

Patent document cited in search repor	t	Publication date		Patent family member(s)	Publication date
WO 9222653	Α	23-12-1992	AU	675916 B	27-02-1997
## 7EEE000	••		AU	2250992 A	12-01-1993
			CA	2103059 A	15-12-1992
			EP	0590058 A	06-04-1994
			ĴΡ	6508267 T	22-09-1994
			WO	9404679 A	03-03-1994
GB 2268744	 А	19-01-1994	AT	129017 T	15-10-1995
			AT	12 4459 T	15-07-1995
			AT	159299 T	15-11-1997
			AU	664801 B	30-11-1995
			AU	6461294 A	22-12-1994
			AU	646009 B	03-02-1994
			AU	6974091 A	24-07-1991
			AU	649645 B	02-06-1994
			AU	7033091 A	24-07-1991
			AU	631481 B	26-11-1992
			AU	7048691 A	24-07-1991
			BG	60462 B	28-04-1995
			CA	2037607 A	07-09-1992
			CA	2 046904 A	22-06-1991
			CA	2050479 A,C	22-06-1991
			DE	69020544 D	03-08-1995
			DE	69020544 T	18-01-1996
			DE	69022982 D	16-11-1995
			DE	69022982 T	28-03-1996
			DE	69031591 D	20-11-1997
			DE	69031591 T	12-03-1998
			DK	460167 T	20-11-1995
			DK	460171 T	28-08-1995
			DK	460178 T	22-12-1997
			EΡ	0460167 A	11-12-1991
			EP	0460171 A	11-12-1991
			EP	046 0 178 A	11-12-1991
			EP	0620276 A	19-10-1994
			EP	0626390 A	30-11-1994
			ES	2079638 T	16-01-1996
			ES	2074701 T	16-09-1995
			ES	2112270 T	01-04-1998
			WO	9109966 A	11-07-1991

Information on patent family members

Intc ional Application No PCT/US 98/06604

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
GB 2268744 A		WO	9109967 A	11-07-1991
		WO	9109968 A	11-07-1991
		GB	2246781 A,B	12-02-1992
		GB	2246570 A,B	05-02-1992
		GB	2268745 A,B	19-01-1994
		GR	3017734 T	31-01-1996
		GR	3025781 T	31-03-1998
		JP	4505398 T	24-09-1992
		JP	4506458 T	12-11-1992
		JP	5500312 T	28-01-1993